Cargando…
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
BACKGROUND: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant therapy. METHODS: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 l...
Autores principales: | Kalanxhi, Erta, Meltzer, Sebastian, Schou, Jakob Vasehus, Larsen, Finn Ole, Dueland, Svein, Flatmark, Kjersti, Jensen, Benny Vittrup, Hole, Knut Håkon, Seierstad, Therese, Redalen, Kathrine Røe, Nielsen, Dorte Lisbet, Ree, Anne Hansen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959927/ https://www.ncbi.nlm.nih.gov/pubmed/29695770 http://dx.doi.org/10.1038/s41416-018-0085-y |
Ejemplares similares
-
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2016) -
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
por: Bains, Simer J., et al.
Publicado: (2019) -
Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic Drugs: Study Design, Multiplex Methods, Molecular Networks
por: Ree, Anne Hansen, et al.
Publicado: (2014) -
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
por: Meltzer, Sebastian, et al.
Publicado: (2019) -
Corrigendum to “Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer” [Transl Oncol 12 (8) (2019) 1038–1044]
por: Meltzer, Sebastian, et al.
Publicado: (2019)